Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet Oncology

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(16)30406-5PMID 27924752PMCID PMC5702534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

  2017cited by this paper
• Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

  2016cited by this paper
• Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

  2016cited by this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer

  2016cited by this paper
• Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

  2016cited by this paper
• Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.

  2016cited by this paper
• CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.

  2016cited by this paper
• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.

  2016cited by this paper
• Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

  2016cited by this paper
• Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

  2016cited by this paper
• Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma

  2016cited by this paper
• Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients.

  2016cited by this paper
• Novel technologies and emerging biomarkers for personalized cancer immunotherapy

  2016cited by this paper
• Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

  2016cited by this paper
• Regulation of PD-L1: a novel role of pro-survival signalling in cancer.

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016cited by this paper
• Programmed death-1 blockade in mismatch repair deficient colorectal cancer.

  2016cited by this paper
• Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

  2016cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer

  2015cited by this paper
• Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma

  2015cited by this paper
• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  2015cited by this paper
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• 15LBA High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients

  2015cited by this paper
• Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

  2015cited by this paper
• Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Neoantigens in cancer immunotherapy

  2015cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

  2014cited by this paper
• Prognostic and predictive markers for the new immunotherapies.

  2014cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

  2014cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

  2013cited by this paper
• Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

  2013cited by this paper
• Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.

  2013cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013cited by this paper
• Innate and adaptive immune cells in the tumor microenvironment

  2013cited by this paper
• Exploiting the mutanome for tumor vaccination.

  2012cited by this paper
• Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer.

  2012cited by this paper
• An immune-active tumor microenvironment favors clinical response to ipilimumab

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting

  2012cited by this paper
• 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

  2012cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper

• Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer

  2026cites this paper
• When genetics meets immunology: the assessment of genetic and immunological backgrounds in advanced NSCLC patients treated with immunotherapy - preliminary study.

  2026cites this paper
• Shaping Immunotherapy Through the Tumor Microenvironment: Translational Perspectives.

  2026cites this paper
• Targeted Induction of Cancer Cell Necroptosis Potentiates Anti-PD-1 Immunotherapy via CD80 Activation

  2026cites this paper
• PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy

  2026cites this paper
• Field-effect-informed urine liquid biopsy for bladder cancer.

  2026cites this paper
• Research progress on the influence of tumor microenvironment on immunotherapy for pancreatic ductal adenocarcinoma

  2026cites this paper
• Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma

  2026cites this paper
• Multi-omics integration and machine learning identify NPC2 as a prognostic and treatment-responsive regulator in lung adenocarcinoma

  2026cites this paper
• Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial

  2026cites this paper
• BRAP Promotes the Tumorigenesis of Hepatocellular Carcinoma by Corrupting Cancer Cell Cycle Regulation and Enhancing Immune Evasion

  2025cites this paper
• The Value of Dynamic of Alkaline Phosphatase and Neutrophil-to-Lymphocyte Ratio in Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Patients with Non-Small Cell Lung Cancer

  2025cites this paper
• A neoantigen-microbead platform for personalized T cell cancer vaccination

  2025cites this paper
• PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

  2025cites this paper
• Developing prognostic models for cholesterol-related genes linked with immune infiltration in prostate cancer

  2025cites this paper
• Identification and validation of an immune-related programmed cell death signature for predicting prognosis and immunotherapy in large-scale multicenter cohorts for lung adenocarcinoma

  2025cites this paper
• Multi-omics profiling unravel the immune landscape diversity by prognostic signatures of immunotherapy response in triple-negative breast cancer

  2025cites this paper
• Review Article: Immunotherapy for Pediatric Malignancies: Benefits and Beyond.

  2025cites this paper
• Integrative analysis of the expression profile and prognostic values of SENP gene family in hepatocellular carcinoma

  2025cites this paper
• Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives

  2025cites this paper
• PD‐L1 Expression is Mediated by microRNA Processing, Wnt/β‐Catenin Signaling, and Chemotherapy in Wilms Tumor

  2025cites this paper
• Insight Into the Significance of CD8+ Tumor‐Infiltrating Lymphocytes in Lung Adenocarcinoma

  2025cites this paper
• Precision oncology for advanced-stage adenocarcinoma of the appendix: comprehensive molecular characterisation identifies actionable lesions and potential predictive biomarkers

  2025cites this paper
• Tumor intrinsic regulation of PD-L1 and of interferon Type I via an SLC25A1-driven mitochondrial pathway, influences the anti-tumor immune response

  2025cites this paper
• Immunogenomic classification and nomogram development and validation for colorectal cancer survival prediction based on immune-related genes

  2025cites this paper
• Deciphering TICRR's oncogenic landscape in pancreatic adenocarcinoma: molecular insights and clinical implications

  2025cites this paper
• Mechanisms of synergistic regulation of the tumor microenvironment by fibroblasts and keratinocytes in esophageal squamous cell carcinoma

  2025cites this paper
• Multi-omics data-based modeling reveals tumorigenesis- and prognosis-associated genes with clinical potential in lung adenocarcinoma

  2025cites this paper
• Analysis of HLA class I allele genotypes and immune-related gene alterations in patients with pan-cancer using whole-exome and whole-genome sequencing.

  2025cites this paper
• Glucose oxidase-powered nanocatalytic medicine: Rewiring tumor metabolism for multimodal cancer therapy

  2025cites this paper
• Characterization and prognostic of CD8 + TIM3 + CD101 + T cells in glioblastoma multiforme

  2025cites this paper
• Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study

  2025cites this paper
• Shared Genomic Features Between Lung Adenocarcinoma and Type 2 Diabetes: A Bioinformatics Study

  2025cites this paper
• CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS.

  2025cites this paper
• A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer

  2025cites this paper
• Analysis of ferritinophagy-related genes associated with the prognosis and regulatory mechanisms in non-small cell lung cancer

  2025cites this paper
• Uncovering global research frontiers in deubiquitinating enzymes and immunotherapy: A bibliometric study

  2025cites this paper
• PD-1/PD-L1 Blockade Based Immunotherapy in Cancer Treatment

  2025cites this paper
• Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy

  2025cites this paper
• 5-Methylcytosine methylation predicts cervical cancer prognosis, shaping immune cell infiltration

  2025cites this paper
• GIMAP8 could serve as a potential prognostic factor for lung adenocarcinoma and is closely related to immunity

  2025cites this paper
• Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab

  2025cites this paper
• Pyroptosis‐Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple‐Negative Breast Cancer

  2025cites this paper
• In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies

  2025cites this paper
• Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report

  2025cites this paper
• Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies

  2025cites this paper
• Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study

  2025cites this paper
• Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy

  2025cites this paper
• Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma

  2025cites this paper
• Protein and Peptide in Cancer Research: From Biomarker to Biotherapeutics

  2025cites this paper
• Low pre-treatment neutrophil-to-lymphocyte ratio predicted a better survival in recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors

  2025cites this paper
• Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions

  2025cites this paper
• DNA methylation profiles predicting response to anti-PD-1-based treatment in patients with advanced gastric cancer

  2025cites this paper
• Immune checkpoint inhibitors in high-grade gastroenteropancreatic neuroendocrine neoplasms.

  2025cites this paper
• CST7+ macrophages/monocytes in melanoma: single-cell insights into immunotherapy response

  2025cites this paper
• Molecular dynamics reveals novel small-molecule inhibitors block PD-1/PD-L1 by promoting PD-L1 dimer stability.

  2025cites this paper
• Translational advancement of immunotherapeutics against pediatric central nervous system tumors.

  2025cites this paper
• Immune checkpoint inhibitor-induced toxicity: a real-world analysis of the role of BMI

  2025cites this paper
• Plant-derived immunomodulators in cancer: Balancing immune activation and suppression within the tumor microenvironment.

  2025cites this paper
• Detection of tumor immune checkpoints: from pathological analysis to functional imaging

  2025influential citation
• Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy

  2025cites this paper
• APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer.

  2025cites this paper
• Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature

  2025cites this paper
• Understanding the molecular bridges between the drugs and immune cell.

  2025cites this paper
• Immune infiltrate populations within distinct tumor immune microenvironments predictive of immune checkpoint treatment outcome

  2025cites this paper
• Prognostic and clinical heterogeneity of PD1 and PD-L1- immunohistochemical scores in endometrial cancers

  2025cites this paper
• Immunological characteristics of peripheral T cells as prognostic markers for Camrelizumab and Apatinib combination therapy in advanced squamous non-small-cell lung cancer.

  2025cites this paper
• Integration of single-cell and bulk RNA-sequencing data to construct and validate a signature based on NK cell marker genes to predict immunotherapy response and prognosis in colorectal cancer

  2025cites this paper
• Novel factors of cisplatin resistance in epithelial ovarian tumours.

  2025cites this paper
• Innovative design of bacterial outer membrane vesicles for vaccine development

  2025cites this paper
• VRK2 promotes colorectal cancer growth and impedes immunotherapy and 5-FU treatment efficacy.

  2025cites this paper
• Transcriptomic profile of RNA pseudouridine modification as a biomarker for cellular senescence associated with survival outcomes in colorectal cancer

  2025cites this paper
• Complete Remission with Nivolumab Monotherapy of Advanced Gastric Neuroendocrine Carcinoma

  2025cites this paper
• Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond.

  2025cites this paper
• The evolving landscape of genetic biomarkers for immunotherapy in primary and metastatic breast cancer

  2025cites this paper
• Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management

  2025cites this paper
• 2D Borophene Nanostructures: Recent Advances in Synthesis, Characterization, and Emerging Applications

  2025cites this paper
• Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma

  2025cites this paper
• Portable Point-of-Care Diagnosis Platforms and Emerging Predictive Biomarkers for Rapid Detection of Severe Dengue Viral Infection

  2025cites this paper
• Prediction of PD-L1 expression in NSCLC patients using PET/CT radiomics and prognostic modelling for immunotherapy in PD-L1-positive NSCLC patients.

  2025cites this paper
• Cohort-based pan-cancer analysis and experimental studies reveal ISG15 gene as a novel biomarker for prognosis and immunotherapy efficacy prediction

  2025cites this paper
• Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer

  2025cites this paper
• Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors

  2025cites this paper
• A Comprehensive Analysis of the Role of DSN1 in Pan-Cancer Prognosis and Immunotherapy

  2025cites this paper
• Bioinformatics analysis of intrinsic drivers of immune dysregulation in multiple myeloma to elucidate immune phenotypes and discover prognostic gene signatures

  2025cites this paper
• Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab

  2025cites this paper
• Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis

  2025cites this paper
• Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications

  2025cites this paper
• Integrative Analysis of EPHX4 as a Novel Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma

  2025cites this paper
• One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma.

  2025cites this paper
• Twenty‐year survival outcomes after multipeptide vaccination for resected high‐risk melanoma: A post‐hoc analysis of a randomized clinical trial

  2025cites this paper
• ImmunoCheckDB: A Comprehensive Platform for Evaluating Cancer Immunotherapy Biomarkers Through Meta‐Analyses and Multiomic Profiling

  2025cites this paper
• Prognostic Significance of Neutrophil‐to‐Lymphocyte Ratio in Melanoma: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Phosphoglycerate kinase 1 as a potential prognostic biomarker in papillary thyroid carcinoma

  2025cites this paper
• Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction

  2025cites this paper
• SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data

  2025cites this paper
• Identification of Core gene expression alterations regulated by gut microbiota in tumor progression and immunotherapy resistance through integrative pan-cancer analysis.

  2025cites this paper
• Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC

  2025cites this paper
• Granzyme B activated near-infrared-II ratiometric fluorescent nanoprobe for early detection of tumor response to immunotherapy

  2025cites this paper
• Advancing precision cancer immunotherapy drug development, administration, and response prediction with AI-enabled Raman spectroscopy

  2025cites this paper